Allostery in a disordered protein: oxidative modifications to α-synuclein act distally to regulate membrane binding.

Both oxidative stress and aggregation of the protein α-synuclein (aS) have been implicated as key factors in the etiology of Parkinson's disease. Specifically, oxidative modifications to aS disrupt its binding to lipid membranes, an interaction considered critical to its native function. Here we seek to provide a mechanistic explanation for this phenomenon by investigating the effects of oxidative nitration of tyrosine residues on the structure of aS and its interaction with lipid membranes. Membrane binding is mediated by the first ∼95 residues of aS. We find that nitration of the single tyrosine (Y39) in this domain disrupts binding due to electrostatic repulsion. Moreover, we observe that nitration of the three tyrosines (Y125/133/136) in the C-terminal domain is equally effective in perturbing binding, an intriguing result given that the C-terminus is not thought to interact directly with the lipid bilayer. Our investigations show that tyrosine nitration results in a change of the conformational states populated by aS in solution, with the most prominent changes occurring in the C-terminal region. These results lead us to suggest that nitration of Y125/133/136 reduces the membrane-binding affinity of aS through allosteric coupling by altering the ensemble of conformational states and depopulating those capable of membrane binding. While allostery is a well-established concept for structured proteins, it has only recently been discussed in the context of disordered proteins. We propose that allosteric regulation through modification of specific residues in, or ligand binding to, the C-terminus may even be a general mechanism for modulating aS function.

[1]  W. Webb,et al.  Quantification of α-Synuclein Binding to Lipid Vesicles Using Fluorescence Correlation Spectroscopy , 2006 .

[2]  D. Lynch,et al.  Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. , 2004, The Journal of biological chemistry.

[3]  E. Rhoades,et al.  Effects of curvature and composition on α-synuclein binding to lipid vesicles. , 2010, Biophysical journal.

[4]  Xiaohui Xu,et al.  Nitrated α-Synuclein Induces the Loss of Dopaminergic Neurons in the Substantia Nigra of Rats , 2010, PloS one.

[5]  V. Hilser,et al.  Intrinsic disorder as a mechanism to optimize allosteric coupling in proteins , 2007, Proceedings of the National Academy of Sciences.

[6]  J. Trojanowski,et al.  Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.

[7]  Ad Bax,et al.  Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. , 2009, Journal of molecular biology.

[8]  S. Lindquist,et al.  α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.

[9]  D. Eliezer,et al.  Charge neutralization and collapse of the C‐terminal tail of alpha‐synuclein at low pH , 2009, Protein science : a publication of the Protein Society.

[10]  Martina Huber,et al.  Spin‐Label EPR on α‐Synuclein Reveals Differences in the Membrane Binding Affinity of the Two Antiparallel Helices , 2008, Chembiochem : a European journal of chemical biology.

[11]  H. Vorum,et al.  Ca2+ Binding to α-Synuclein Regulates Ligand Binding and Oligomerization* , 2001, The Journal of Biological Chemistry.

[12]  Adam J. Trexler,et al.  Alpha-synuclein binds large unilamellar vesicles as an extended helix. , 2009, Biochemistry.

[13]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[14]  E. Bergantino,et al.  The reaction of alpha-synuclein with tyrosinase: possible implications for Parkinson disease. , 2008, The Journal of biological chemistry.

[15]  Zhou Yu,et al.  The induction of folding cooperativity by ligand binding drives the allosteric response of tetracycline repressor , 2009, Proceedings of the National Academy of Sciences.

[16]  Adam J. Trexler,et al.  Single molecule characterization of α-synuclein in aggregation-prone states. , 2010, Biophysical journal.

[17]  Ralf Langen,et al.  Structure of membrane-bound α-synuclein studied by site-directed spin labeling , 2004 .

[18]  L. Forno,et al.  Pathologic Modifications of &agr;-Synuclein in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Treated Squirrel Monkeys , 2008, Journal of neuropathology and experimental neurology.

[19]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[20]  Robert Edwards,et al.  Lipid Rafts Mediate the Synaptic Localization of α-Synuclein , 2004, The Journal of Neuroscience.

[21]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[22]  E. Masliah,et al.  Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits α-Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions , 2010, The Journal of Neuroscience.

[23]  D E Wemmer,et al.  Two-state allosteric behavior in a single-domain signaling protein. , 2001, Science.

[24]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[25]  M. Akke,et al.  Structural dynamics in the C-terminal domain of calmodulin at low calcium levels. , 1999, Journal of molecular biology.

[26]  P. Lansbury,et al.  Phosphorylation at Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of α-Synuclein* , 2008, Journal of Biological Chemistry.

[27]  Martin Blackledge,et al.  Amino acid bulkiness defines the local conformations and dynamics of natively unfolded alpha-synuclein and tau. , 2007, Journal of the American Chemical Society.

[28]  D. Eliezer,et al.  Residual Structure and Dynamics in Parkinson's Disease-associated Mutants of α-Synuclein* , 2001, The Journal of Biological Chemistry.

[29]  P. Højrup,et al.  α-Synuclein Binds to Tau and Stimulates the Protein Kinase A-catalyzed Tau Phosphorylation of Serine Residues 262 and 356* , 1999, The Journal of Biological Chemistry.

[30]  M. Goedert,et al.  Binding of α-Synuclein to Brain Vesicles Is Abolished by Familial Parkinson’s Disease Mutation* , 1998, The Journal of Biological Chemistry.

[31]  D. Eliezer,et al.  A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. , 2003, Journal of molecular biology.

[32]  S. Lindquist,et al.  α-Synuclein: membrane interactions and toxicity in Parkinson's disease. , 2010, Annual review of cell and developmental biology.

[33]  J. Benovic,et al.  Synucleins Are a Novel Class of Substrates for G Protein-coupled Receptor Kinases* , 2000, The Journal of Biological Chemistry.

[34]  Elisha Haas,et al.  Segmental conformational disorder and dynamics in the intrinsically disordered protein α-synuclein and its chain length dependence. , 2011, Journal of molecular biology.

[35]  Jonathan A. Jones,et al.  Characterisation of protein unfolding by NMR diffusion measurements , 1997 .

[36]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[37]  R. Perrin,et al.  Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. , 2000, The Journal of biological chemistry.

[38]  P. Karplus,et al.  Crystal Structure of the Antioxidant Enzyme Glutathione Reductase Inactivated by Peroxynitrite* , 2002, The Journal of Biological Chemistry.

[39]  H. Lashuel,et al.  E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. , 2009, Journal of molecular biology.

[40]  J. Kenney,et al.  Microtubule-associated Protein 1B Is a Component of Cortical Lewy Bodies and Binds α-Synuclein Filaments* , 2000, The Journal of Biological Chemistry.

[41]  R Nussinov,et al.  Point mutations and sequence variability in proteins: Redistributions of preexisting populations , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Haass,et al.  Physiology and Pathophysiology of α‐Synuclein: Cell Culture and Transgenic Animal Models Based on a Parkinson's Disease‐associated Protein , 2000, Annals of the New York Academy of Sciences.

[43]  S. Lindquist,et al.  Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology , 2003, Science.

[44]  Martina Huber,et al.  Direct evidence of coexisting horseshoe and extended helix conformations of membrane-bound alpha-synuclein. , 2011, Chemphyschem : a European journal of chemical physics and physical chemistry.

[45]  R. Ranganathan,et al.  Evolutionarily conserved pathways of energetic connectivity in protein families. , 1999, Science.

[46]  C. Griesinger,et al.  Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[47]  B. Vallee,et al.  Tetranitromethane. A reagent for the nitration of tyrosyl residues in proteins. , 1966, Biochemistry.

[48]  Luca Pinato,et al.  A Topological Model of the Interaction between α-Synuclein and Sodium Dodecyl Sulfate Micelles† , 2005 .

[49]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[50]  B. Giasson,et al.  Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. , 2000, The Journal of biological chemistry.

[51]  M. Goedert,et al.  Cysteine misincorporation in bacterially expressed human α‐synuclein , 2006 .

[52]  C. Griesinger,et al.  Familial Mutants of α-Synuclein with Increased Neurotoxicity Have a Destabilized Conformation* , 2005, Journal of Biological Chemistry.

[53]  E. Daikhin,et al.  Proteolytic degradation of tyrosine nitrated proteins. , 2000, Archives of biochemistry and biophysics.

[54]  C. Dobson,et al.  Differential Phospholipid Binding of α-Synuclein Variants Implicated in Parkinson’s Disease Revealed by Solution NMR Spectroscopy† , 2009, Biochemistry.

[55]  T. Südhof,et al.  α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro , 2010, Science.

[56]  C. Dobson,et al.  Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. , 2005, Journal of the American Chemical Society.

[57]  C. Griesinger,et al.  Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. , 2006, Journal of the American Chemical Society.

[58]  D. Eliezer,et al.  Conformational properties of alpha-synuclein in its free and lipid-associated states. , 2001, Journal of molecular biology.

[59]  M. Ebadi,et al.  Reactive Macrophages Increase Oxidative Stress and Alpha-Synuclein Nitration During Death of Dopaminergic Neuronal Cells in Co-Culture: Relevance to Parkinson’s Disease , 2005, Neurochemical Research.

[60]  Reinhard Jahn,et al.  A Broken α-Helix in Folded α-Synuclein* , 2003, The Journal of Biological Chemistry.

[61]  Birgit Schilling,et al.  Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease. , 2009, Analytical chemistry.

[62]  M. Blackledge,et al.  Defining long-range order and local disorder in native alpha-synuclein using residual dipolar couplings. , 2005, Journal of the American Chemical Society.